Promising Phase II Results for Agenus' Brain Cancer Vaccine

July 1, 2014 1:55 PM

6 0

Promising Phase II Results for Agenus' Brain Cancer Vaccine

The Phase II results are in for Agenus' autologous cancer vaccine Prophage: According to the immuno-oncology firm, the single-arm, multi-institutional, open-label study showed that patients with newly diagnosed glioblastoma multiforme (GBM) who received Prophage in addition to the standard of care treatment lived nearly twice as long as expected.

Patients treated with the vaccine also had a median progression-free survival (PFS) of nearly 18 months; Agenus says this is around two to three-times longer than patients treated with radiation and temozolomide alone. Also, 22% of patients were alive and without progression at 24 months.

Read more

To category page

Loading...